1. Home
  2. OPTH vs ACET Comparison

OPTH vs ACET Comparison

Compare OPTH & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Optimi Health Corp. Common Shares

OPTH

Optimi Health Corp. Common Shares

N/A

Current Price

$2.22

Market Cap

28.9M

Sector

N/A

ML Signal

N/A

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

N/A

Current Price

$2.95

Market Cap

28.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OPTH
ACET
Founded
2020
1947
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.9M
28.0M
IPO Year
2024
2017

Fundamental Metrics

Financial Performance
Metric
OPTH
ACET
Price
$2.22
$2.95
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $29.00
AVG Volume (30 Days)
35.6K
★ 215.0K
Earning Date
12-08-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$56.17
N/A
Revenue Next Year
$82.70
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.90
$0.46
52 Week High
$5.45
$9.97

Technical Indicators

Market Signals
Indicator
OPTH
ACET
Relative Strength Index (RSI) 31.88 19.20
Support Level $1.90 N/A
Resistance Level $5.21 $9.51
Average True Range (ATR) 0.37 0.25
MACD 0.02 0.09
Stochastic Oscillator 21.43 9.88

Price Performance

Historical Comparison
OPTH
ACET

About OPTH Optimi Health Corp. Common Shares

Optimi Health Corp operates in developing a vertically integrated Canadian functional mushroom brand that focuses on the health and wellness sector. The company has one reportable operating segment being that of the farming, processing, and distribution of raw mushroom biomass. It also intends to cultivate, extract, process, and distribute strains of fungi products at its facilities located in Princeton, British Columbia.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Share on Social Networks: